933 related articles for article (PubMed ID: 15289858)
1. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
2. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
[TBL] [Abstract][Full Text] [Related]
3. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
4. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
6. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
8. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
[TBL] [Abstract][Full Text] [Related]
9. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
11. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
Murakami Y; Kazuno H; Emura T; Tsujimoto H; Suzuki N; Fukushima M
Int J Oncol; 2000 Aug; 17(2):277-83. PubMed ID: 10891536
[TBL] [Abstract][Full Text] [Related]
12. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
13. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
[TBL] [Abstract][Full Text] [Related]
14. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
17. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
18. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
19. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
20. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
